Literature DB >> 15647237

Medicare's national coverage decisions, 1999-2003: quality of evidence and review times.

Peter J Neumann1, Nomita Divi, Molly T Beinfeld, Bat-Sheva Levine, Patricia Seliger Keenan, Elkan F Halpern, G Scott Gazelle.   

Abstract

In 1998 Medicare amended its procedures for making national coverage decisions for new technologies in an attempt to make the process more transparent and evidence based. We examined the quality of evidence for sixty-nine technologies reviewed by Medicare since then. Determinations by the Centers for Medicare and Medicaid Services (CMS) have generally been consistent with the strength of evidence. Good clinical evidence from rigorous studies is usually lacking for the technologies Medicare considers, although in most cases the CMS covers with conditions if there is at least fair evidence that benefits outweigh harms. Decisions referred to the external Medicare Coverage Advisory Committee (MCAC) have averaged eight months longer than non-MCAC decisions.

Entities:  

Mesh:

Year:  2005        PMID: 15647237     DOI: 10.1377/hlthaff.24.1.243

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 2.  Economic evaluation in the US: what is the missing link?

Authors:  Peter J Neumann; Sean D Sullivan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  The impact of Medicare coverage policies on health care utilization.

Authors:  Susan Bartlett Foote; Beth A Virnig; Robert J Town; Lacey Hartman
Journal:  Health Serv Res       Date:  2008-05-12       Impact factor: 3.402

Review 4.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

5.  Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.

Authors:  Aliya C Roginiel; Sanket S Dhruva; Joseph S Ross
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.